Atrial fibrillation (AF), the most common sustained arrhythmia in the population, imposes a large and growing burden on patients and the health care system alike. This rhythm is associated with substantial morbidity and impairment in health-related quality of life for many of the over 2 million U.S. citizens who suffer from it, leading to the development of aggressive techniques for eliminating its occurrence or palliating its effects. Electrical isolation of the pulmonary veins from the left atrium with radiofrequency catheter ablation has recently emerged as an important new therapy for AF. Promising early results with these techniques have generated considerable enthusiasm for the ablation approach, such that many centers are now offering it as standard therapy despite the current lack of prospective randomized data addressing its safety and efficacy. The proposed research plan has the overall goal of developing a cost-effectiveness model for comparing AF ablation with alternative therapeutic strategies. The data generated will be useful for physicians and patients who must make decisions about these therapies in the face of imperfect information. Several preliminary steps will be needed in order to develop a robust cost-effectiveness model in this area. Chief among these will be to develop a better understanding of the determinants of quality of life and health care resource utlization in the AF population.These questions will be addressed through analysis of an ongoing 1000 patient national registry of new onset AF patients. In addition, the utility weights needed to calculate quality adjusted life years (QALYs) - the preferred unit of effectiveness in cost-effectiveness analysis - have never been measured. Thus, procedural costs, quality of life, and utilities will be measured prospectively in patients undergoing AF ablation. Once all of this data is collected, the necessary inputs will combined in a Markov model comparing AF ablation with antiarrhythmic drug therapy, and atrio-ventricular junctional ablation with pacemaker implantation.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23HL077171-03
Application #
7086945
Study Section
Special Emphasis Panel (ZHL1-CSR-J (M1))
Program Officer
Scott, Jane
Project Start
2004-07-15
Project End
2009-06-30
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
3
Fiscal Year
2006
Total Cost
$119,799
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Martin-Doyle, William; Essebag, Vidal; Zimetbaum, Peter et al. (2011) Trends in US hospitalization rates and rhythm control therapies following publication of the AFFIRM and RACE trials. J Cardiovasc Electrophysiol 22:548-53
Fein, Adam S; Wang, Yongfei; Curtis, Jeptha P et al. (2010) Prevalence and predictors of off-label use of cardiac resynchronization therapy in patients enrolled in the National Cardiovascular Data Registry Implantable Cardiac-Defibrillator Registry. J Am Coll Cardiol 56:766-73
Martin-Doyle, William; Reynolds, Matthew R (2010) Is AF Ablation Cost Effective? J Atr Fibrillation 2:727-739
Darge, Alicia; Reynolds, Matthew R; Germano, Joseph J (2009) Advances in atrial fibrillation ablation. J Invasive Cardiol 21:247-54
Ellis, Ethan R; Culler, Steven D; Simon, April W et al. (2009) Trends in utilization and complications of catheter ablation for atrial fibrillation in Medicare beneficiaries. Heart Rhythm 6:1267-73
Reynolds, Matthew R; Zimetbaum, Peter; Josephson, Mark E et al. (2009) Cost-effectiveness of radiofrequency catheter ablation compared with antiarrhythmic drug therapy for paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol 2:362-9
Wylie Jr, John V; Essebag, Vidal; Reynolds, Matthew R et al. (2009) Inducibility of atrial fibrillation with a synchronized external low energy shock post-pulmonary vein isolation predicts recurrent atrial fibrillation. J Cardiovasc Electrophysiol 20:29-36
Cohen, David J; Reynolds, Matthew R (2008) Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol 52:2119-26
Reynolds, Matthew R; Ellis, Ethan; Zimetbaum, Peter (2008) Quality of life in atrial fibrillation: measurement tools and impact of interventions. J Cardiovasc Electrophysiol 19:762-8
Reddy, Vivek Y; Reynolds, Matthew R; Neuzil, Petr et al. (2007) Prophylactic catheter ablation for the prevention of defibrillator therapy. N Engl J Med 357:2657-65

Showing the most recent 10 out of 21 publications